Last reviewed · How we verify
Actrapid® (Insulin)
Actrapid is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Actrapid is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | Actrapid® (Insulin) |
|---|---|
| Also known as | insulin |
| Sponsor | SepNet - Critical Care Trials Group |
| Drug class | Insulin (short-acting/rapid-acting) |
| Target | Insulin receptor (IR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Actrapid (human insulin injection) mimics endogenous insulin by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This results in rapid reduction of postprandial and fasting blood glucose levels. It is a short-acting insulin formulation designed for mealtime glucose control in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
- Weight gain
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women (NA)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) (PHASE2)
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actrapid® (Insulin) CI brief — competitive landscape report
- Actrapid® (Insulin) updates RSS · CI watch RSS
- SepNet - Critical Care Trials Group portfolio CI